Trials / Approved For Marketing
Approved For MarketingNCT04148092
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
Expanded Access Program for Ripretinib in Patients With Locally Advanced Unresectable or Metastatic GIST Who Have Received Treatment With Prior Therapies
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Deciphera Pharmaceuticals, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an open-label, single-arm, multicenter expanded access study to provide patients who have locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST) and have received treatment with at least 2 prior Food and Drug Administration (FDA)-approved therapies early access to ripretinib until such time that ripretinib becomes commercially available or the Sponsor chooses to discontinue the program.
Detailed description
The EAP is no longer enrolling patients in the United States.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ripretinib | orally administered solid dosage form |
Timeline
- First posted
- 2019-11-01
- Last updated
- 2020-05-29
Source: ClinicalTrials.gov record NCT04148092. Inclusion in this directory is not an endorsement.